Article
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Oncogene - 18 Oct 2012
Ratner E S, Keane F K, Lindner R, Tassi R A, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller R-U, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea M C, Yu H, Rutherford T J, Weitzel J N, Neuhausen S L, Schwartz P E, Slack F J, Santin A D, Weidhaas J B
Abstract excerpt
Germline variants in the 3' untranslated region (3'UTR) of cancer genes disrupting microRNA (miRNA) regulation have recently been associated with cancer risk. A variant in the 3'UTR of the KRAS oncogene, referred to as the KRAS variant, is associated with both cancer risk and altered tumor biology. Here, we test the hypothesis that the KRAS variant can act as a biomarker of outcome in epithelial ovarian cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.